中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2014年
19期
97-97,98
,共2页
氨溴索注射液%小儿支原体肺炎%疗效
氨溴索註射液%小兒支原體肺炎%療效
안추색주사액%소인지원체폐염%료효
Ambroxol Injection%pediatric mycoplasma pneumonia%efficacy
目的:观察氨溴索注射液在治疗小儿支原体肺炎中的临床效果。方法将112例支原体肺炎患儿随机分为治疗组和对照组,各56例,其中对照组给予常规治疗,治疗组在对照组基础上加用氨溴索注射液。疗程结束后,比较两组患者的临床疗效和治疗后患儿症状改善情况。结果治疗组总有效率高达91.07%,明显高于对照组的80.36%( P<0.05);治疗组的发热缓解时间、咳嗽消失时间、肺部罗音消失时间、胸部X线摄片改善时间以及住院时间均显著短于对照组( P<0.05)。结论氨溴索注射液治疗小儿支原体肺炎,可在短时间内缓解发热、咳嗽、肺罗音等临床症状,临床效果显著。
目的:觀察氨溴索註射液在治療小兒支原體肺炎中的臨床效果。方法將112例支原體肺炎患兒隨機分為治療組和對照組,各56例,其中對照組給予常規治療,治療組在對照組基礎上加用氨溴索註射液。療程結束後,比較兩組患者的臨床療效和治療後患兒癥狀改善情況。結果治療組總有效率高達91.07%,明顯高于對照組的80.36%( P<0.05);治療組的髮熱緩解時間、咳嗽消失時間、肺部囉音消失時間、胸部X線攝片改善時間以及住院時間均顯著短于對照組( P<0.05)。結論氨溴索註射液治療小兒支原體肺炎,可在短時間內緩解髮熱、咳嗽、肺囉音等臨床癥狀,臨床效果顯著。
목적:관찰안추색주사액재치료소인지원체폐염중적림상효과。방법장112례지원체폐염환인수궤분위치료조화대조조,각56례,기중대조조급여상규치료,치료조재대조조기출상가용안추색주사액。료정결속후,비교량조환자적림상료효화치료후환인증상개선정황。결과치료조총유효솔고체91.07%,명현고우대조조적80.36%( P<0.05);치료조적발열완해시간、해수소실시간、폐부라음소실시간、흉부X선섭편개선시간이급주원시간균현저단우대조조( P<0.05)。결론안추색주사액치료소인지원체폐염,가재단시간내완해발열、해수、폐라음등림상증상,림상효과현저。
Objective To observe the clinical effects of Ambroxol Injection in the treatment of pediatric mycoplasma pneumonia. Methods 112 cases of pediatric mycoplasma pneumonia in our hospital were randomly divided into the treatment group and the control group, 56 cases in each group. The control group wwas treated with the routine therapy, while on this basis the treatment group was added with the treatment of Ambroxol Injection. The clinical efficacy and symptomatic improvement after treatment were compared between the two groups. Results The total effective rate of the treatment group reached up to 91. 07%, while which of the control group was 80. 36%, the statistical difference existed between the two groups ( P<0. 05 );the fever relief time, cough disappearance time, pulmonary rales dis-appearance time, X-ray improvement time and hospitalization duration in the treatment group were significantly shorter than those in the control group with statistical differences ( P<0. 05 ) . Conclusion Ambroxol Injection can alleviate the symptoms of fever, cough and pulmonary rales in a short time with significant clinical efficacy in the treatment of mycoplasma pneumonia.